Genprex research links TROP2 expression to REQORSA efficacy, suggesting that low levels of the protein may serve as a marker for primary treatment resistance in lung cancer patients.
Genprex announced research linking TROP2 expression to REQORSA treatment response, with low TROP2 associated with primary resistance. The findings may help guide patient selection but are early-stage and include no financial or regulatory updates, so the stock price is unlikely to move materially.
Genprex announced new research identifying TROP2 expression as a potential predictive biomarker for its REQORSA gene therapy in lung cancer patients. The study indicates that low TROP2 levels are linked to primary resistance, offering a potential pathway to refine patient selection for future clinical trials.
TROP2 serves as a potential predictive biomarker that helps determine which lung cancer patients are more likely to respond to REQORSA gene therapy.